ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2014
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.
Article in American journal of physiology. Regulatory, integrative and comparative physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 175 citations in OpenAlex.
- Foregut Exclusion Enhances Incretin and Insulin Secretion After Roux-en-Y Gastric Bypass in Adults With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2021Trial
- Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery.Cell reports · 2019Trial
- Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity.The Journal of clinical endocrinology and metabolism · 2016Trial
- Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.Neuropharmacology · 2025Review
- Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.Pflugers Archiv : European journal of physiology · 2025Review
- Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.Frontiers in endocrinology · 2025Article
- Gut microbiota turn up the heat after bariatric surgery.Cell stress · 2023Article
- A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.Scientific reports · 2023Article
- Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period.Scientific reports · 2023Article
- The PYY/Y2R-deficient male mouse is not protected from bone loss due to Roux-en-Y gastric bypass.Bone · 2023Article
- Regulation of body weight: Lessons learned from bariatric surgery.Molecular metabolism · 2023Review
- Effects of bariatric surgery on drug pharmacokinetics-Preclinical studies.Frontiers in pharmacology · 2023Review
- Regulation of Pancreatic TXNIP-Insulin Expression Levels after Bariatric Surgery Using Diabetic Rodent Model.BioMed research international · 2023Article
- The Neural Code for Taste in the Nucleus of the Solitary Tract of Rats with Obesity Following Roux-En-Y Gastric Bypass Surgery.Nutrients · 2022Article
- Metabolic Profile and Metabolite Analyses in Extreme Weight Responders to Gastric Bypass Surgery.Metabolites · 2022Article
- Consistent gut bacterial and short-chain fatty acid signatures in hypoabsorptive bariatric surgeries correlate with metabolic benefits in rats.International journal of obesity (2005) · 2022Article
- Mechanisms of Weight Loss After Obesity Surgery.Endocrine reviews · 2022Review
- Article
- Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.Frontiers in endocrinology · 2022Article
- Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Exaggerated GLP-1 and PYY secretion is thought to be a major mechanism in the reduced food intake and body weight after Roux-en-Y gastric bypass surgery. Here, we use complementary pharmacological and genetic loss-of-function approaches to test the role of increased signaling by these gut hormones in high-fat diet-induced obese rodents. Chronic brain infusion of a supramaximal dose of the selective GLP-1 receptor antagonist exendin-9-39 into the lateral cerebral ventricle significantly increased food intake and body weight in both RYGB and sham-operated rats, suggesting that, while contributing to the physiological control of food intake and body weight, central GLP-1 receptor signaling tone is not the critical mechanism uniquely responsible for the body weight-lowering effects of RYGB. Central infusion of the selective Y2R-antagonist BIIE0246 had no effect in either group, suggesting that it is not critical for the effects of RYGB on body weight under the conditions tested. In a recently established mouse model of RYGB that closely mimics surgery and weight loss dynamics in humans, obese GLP-1R-deficient mice lost the same amount of body weight and fat mass and maintained similarly lower body weight compared with wild-type mice. Together, the results surprisingly provide no support for important individual roles of either gut hormone in the specific mechanisms by which RYGB rats settle at a lower body weight. It is likely that the beneficial effects of bariatric surgeries are expressed through complex mechanisms that require combination approaches for their identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.